|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US7041871B1
(en)
*
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
BRPI9707379C8
(pt)
|
1996-02-09 |
2017-12-12 |
Abbott Biotech Ltd |
composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
|
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
|
ES2301183T3
(es)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
Anticuerpo completamente humano que se une al receptor del egfr.
|
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
|
US7666609B1
(en)
|
1998-12-01 |
2010-02-23 |
Shanghai Cp Guojian Pharmaceutical Co. Ltd. |
Method and composition for diagnosis of melanocytic lesions
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
SG143018A1
(en)
|
1998-12-23 |
2008-06-27 |
Pfizer |
Human monoclonal antibodies to ctla-4
|
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
DK1210374T3
(da)
*
|
1999-07-29 |
2007-02-19 |
Medarex Inc |
Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
|
US7030228B1
(en)
|
1999-11-15 |
2006-04-18 |
Miltenyi Biotec Gmbh |
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
|
|
US7820878B2
(en)
*
|
1999-11-19 |
2010-10-26 |
Kyowa Hakko Kirin Co., Ltd. |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
|
US7074983B2
(en)
*
|
1999-11-19 |
2006-07-11 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
|
|
US7414170B2
(en)
*
|
1999-11-19 |
2008-08-19 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovines capable of human antibody production
|
|
WO2001035735A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Hematech, Llc |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
|
JP2001211882A
(ja)
*
|
2000-01-31 |
2001-08-07 |
Shiyuuji Miyagawa |
移植関連タンパク質をコードするコドン改変型遺伝子
|
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
AU2001297523B2
(en)
|
2000-11-17 |
2007-01-18 |
Sab, Llc |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
|
KR100857943B1
(ko)
*
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
|
KR100832943B1
(ko)
|
2000-12-22 |
2008-05-27 |
기린 파마 가부시끼가이샤 |
재구성된 공여체 염색질 또는 공여체 세포를 이용한 포유류의 클로닝방법
|
|
US20020142397A1
(en)
*
|
2000-12-22 |
2002-10-03 |
Philippe Collas |
Methods for altering cell fate
|
|
US7491534B2
(en)
|
2000-12-22 |
2009-02-17 |
Kirin Holdings Kabushiki Kaisha |
Methods for altering cell fate to generate T-cells specific for an antigen of interest
|
|
IL157274A0
(en)
|
2001-02-12 |
2004-02-19 |
Medarex Inc |
Human monoclonal antibodies to fc alpha receptor (cd89)
|
|
WO2002092812A1
(fr)
*
|
2001-05-11 |
2002-11-21 |
Kirin Beer Kabushiki Kaisha |
CHROMOSOME HUMAIN ARTIFICIEL CONTENANT LE GENE A CHAINE LEGERE DE L'ANTICORPS HUMAIN $g(l)
|
|
GB0115256D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
US7084257B2
(en)
*
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
EP1448588A4
(en)
|
2001-10-23 |
2006-10-25 |
Psma Dev Company L L C |
ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
EP3269235B1
(en)
*
|
2001-11-30 |
2022-01-26 |
Amgen Fremont Inc. |
Transgenic mice bearing human ig lambda light chain genes
|
|
IL162111A0
(en)
*
|
2001-12-22 |
2005-11-20 |
4Antibody Ag |
Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
|
|
CN1638800A
(zh)
|
2002-01-09 |
2005-07-13 |
米德列斯公司 |
抗cd30的人类单克隆抗体
|
|
ATE431406T1
(de)
|
2002-02-25 |
2009-05-15 |
Genentech Inc |
Neuer typ-1-cytokinrezeptor glm-r
|
|
CA2481074A1
(en)
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
|
ATE552849T1
(de)
|
2002-04-12 |
2012-04-15 |
Medarex Inc |
Behandlungsverfahren unter verwendung von ctla-4 antikörpern
|
|
GB2387599B
(en)
*
|
2002-04-17 |
2005-08-10 |
Jason Peter Brown |
Methods for producing antibodies
|
|
KR20050000558A
(ko)
|
2002-05-17 |
2005-01-05 |
헤마테크, 엘엘씨 |
인간 항체를 제조할 수 있는 트랜스제닉 유제동물
|
|
EP2316921B1
(en)
|
2002-05-24 |
2014-05-14 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-IGFR antibody
|
|
US7438910B2
(en)
|
2002-09-06 |
2008-10-21 |
Amgen Inc. |
Therapeutic human anti-IL1-R1 monoclonal antibody
|
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
|
PT1558648E
(pt)
|
2002-10-17 |
2012-04-23 |
Genmab As |
Anticorpos monoclonais humanos contra cd20
|
|
AU2003286515A1
(en)
*
|
2002-10-21 |
2004-05-13 |
Regents Of The University Of Minnesota |
Transgenic non-human animals with expanded mature b cell and plasma cell populations
|
|
AU2003290689A1
(en)
*
|
2002-11-08 |
2004-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Transgenic ungulates having reduced prion protein activity and uses thereof
|
|
NZ540555A
(en)
|
2002-11-15 |
2008-04-30 |
Genmab As |
Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
|
|
CA2508375C
(en)
|
2002-12-02 |
2014-05-27 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
|
ATE527278T1
(de)
*
|
2002-12-16 |
2011-10-15 |
Genmab As |
Humane monoklonale antikörper gegen interleukin 8 (il-8)
|
|
ZA200506202B
(en)
|
2003-01-31 |
2006-10-25 |
Celldex Therapeutics Inc |
Antibody vaccine conjugates and uses therefor
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
AU2004224390A1
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
|
CN101318019B
(zh)
|
2003-04-23 |
2012-08-29 |
梅达雷克斯公司 |
含1型干扰素拮抗剂的组合物及其在制备治疗炎症性肠病的药物中的用途
|
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
|
EP3037105B1
(en)
|
2003-06-27 |
2021-03-17 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
TWI503328B
(zh)
*
|
2003-07-15 |
2015-10-11 |
Amgen Inc |
作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
|
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
|
JP4680902B2
(ja)
*
|
2003-07-22 |
2011-05-11 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
Ｒｇ１抗体及びその使用
|
|
US7396914B2
(en)
|
2003-08-04 |
2008-07-08 |
University Of Massachusetts |
SARS nucleic acids, proteins, antibodies, and uses thereof
|
|
BR0318454A
(pt)
|
2003-08-08 |
2006-09-12 |
Abgenix Inc |
anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
|
|
ATE455174T1
(de)
|
2003-09-23 |
2010-01-15 |
Univ North Carolina |
Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
|
|
PL2189523T3
(pl)
|
2003-10-14 |
2012-05-31 |
Baxalta Inc |
Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
|
|
CA2545755A1
(en)
|
2003-11-12 |
2005-05-26 |
Schering Corporation |
Plasmid system for multigene expression
|
|
EP1533617A1
(en)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
|
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
KR101151477B1
(ko)
|
2003-12-10 |
2012-06-22 |
메다렉스, 인코포레이티드 |
인터페론 알파 항체 및 그의 용도
|
|
SI2383295T1
(sl)
|
2003-12-10 |
2015-07-31 |
E.R. Squibb & Sons, L.L.C. |
Protitelesa IP-10 in njihova uporaba
|
|
JP4588763B2
(ja)
|
2004-02-06 |
2010-12-01 |
ユニバーシティー オブ マサチューセッツ |
クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
|
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
WO2005104835A2
(en)
|
2004-04-22 |
2005-11-10 |
Kirin Beer Kabushiki Kaisha |
Transgenic animals and uses thereof
|
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
|
BRPI0511755A
(pt)
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
|
CA2568661A1
(en)
|
2004-06-03 |
2006-01-05 |
Medarex, Inc. |
Human monoclonal antibodies to fc gamma receptor i (cd64)
|
|
JP5160887B2
(ja)
|
2004-06-21 |
2013-03-13 |
メダレックス インコーポレイテッド |
インターフェロンアルファレセプター１抗体及びその使用法
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
MX2007001221A
(es)
|
2004-08-04 |
2007-03-23 |
Amgen Inc |
Anticuerpos para proteina dickkopf-1 (dkk-1).
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP2008514730A
(ja)
|
2004-10-01 |
2008-05-08 |
メダレックス， インク． |
Ｃｄ３０陽性リンパ腫の処置の方法
|
|
US7785591B2
(en)
*
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
|
NZ554824A
(en)
|
2004-10-22 |
2010-10-29 |
Revivicor Inc |
Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
|
|
JP2008520684A
(ja)
|
2004-11-17 |
2008-06-19 |
アブジェニックス・インコーポレーテッド |
Ｉｌ−１３に対する完全ヒトモノクローナル抗体
|
|
WO2006059106A2
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
EP2281841A3
(en)
*
|
2004-12-03 |
2013-10-23 |
Merck Sharp & Dohme Corp. |
Biomarkers for pre-selection of patients for anti-IGF1R therapy
|
|
DE602005027399D1
(de)
|
2004-12-20 |
2011-05-19 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
|
US20080267971A1
(en)
|
2004-12-21 |
2008-10-30 |
Green Larry L |
Antibodies Directed to Angiopoietin-2 and Uses Thereof
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2006081139A2
(en)
|
2005-01-26 |
2006-08-03 |
Abgenix, Inc. |
Antibodies against interleukin-1 beta
|
|
US8207303B2
(en)
|
2005-02-18 |
2012-06-26 |
Medarex, Inc. |
Monoclonal antibodies against CD30 lacking in fucosyl residues
|
|
DK1861711T3
(da)
|
2005-03-11 |
2012-04-16 |
Sanofi Sa |
Anvendelse af MGC4504
|
|
US20090325226A1
(en)
|
2005-03-15 |
2009-12-31 |
Stafford Darrel W |
Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
|
|
EA037929B1
(ru)
|
2005-03-23 |
2021-06-08 |
Генмаб А/С |
Антитела к cd38 человека и их применение
|
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
JP2008539742A
(ja)
|
2005-05-11 |
2008-11-20 |
サノフィ−アベンティス |
Ｇｉｐプロモーター多型の使用
|
|
AU2006249087B2
(en)
|
2005-05-20 |
2012-05-17 |
Lonza Biologics Plc |
High-level expression of recombinant antibody in a mammalian host cell
|
|
EP1893756B1
(en)
*
|
2005-06-08 |
2015-08-12 |
The Regents of The University of California |
Elimination of n-glycolylneuraminic acid from mammalian products for human use
|
|
NZ564098A
(en)
*
|
2005-06-15 |
2010-04-30 |
Schering Corp |
Anti-IGF1R antibody formulations
|
|
PT1896073E
(pt)
|
2005-06-30 |
2013-05-28 |
Janssen Biotech Inc |
Composições, métodos e aplicações de anticorpos anti-il-23
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
CA2854576A1
(en)
|
2005-07-18 |
2007-01-25 |
Haichun Huang |
Human anti-b7rp1 neutralizing antibodies
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
|
EP1957530A2
(en)
|
2005-10-21 |
2008-08-20 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
EP1957115B8
(en)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
|
NZ568016A
(en)
|
2005-12-07 |
2011-12-22 |
Medarex Inc |
CTLA-4 antibody dosage escalation regimens
|
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
AU2007207764B2
(en)
|
2006-01-12 |
2012-06-07 |
Alexion Pharmaceuticals, Inc. |
Antibodies to OX-2/CD200 and uses thereof
|
|
US20090175886A1
(en)
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
|
MX2008012023A
(es)
*
|
2006-03-21 |
2008-10-01 |
Wyeth Corp |
Metodos para prevenir y tratar enfermedades amiloidogenicas.
|
|
AU2007235496B2
(en)
|
2006-03-31 |
2013-11-21 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
|
JP2009533028A
(ja)
|
2006-04-07 |
2009-09-17 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
新生物疾患の治療のための抗体組成物および方法
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
JP5362563B2
(ja)
|
2006-08-03 |
2013-12-11 |
アストラゼネカ・アクチエボラーグ |
αＶβ６に対する抗体およびその使用
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
ES2396220T3
(es)
|
2006-08-11 |
2013-02-20 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
|
|
EA200970250A1
(ru)
|
2006-09-05 |
2010-02-26 |
Медарекс, Инк. |
Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
|
|
ME03503B
(me)
|
2006-09-26 |
2020-04-20 |
Genmab As |
Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora
|
|
JP2010504955A
(ja)
|
2006-09-28 |
2010-02-18 |
メルク セローノ ソシエテ アノニム |
接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
|
|
ME02269B
(me)
|
2006-10-02 |
2016-04-28 |
Medarex Inc |
Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
|
|
EP2530090A3
(en)
|
2006-10-19 |
2013-01-23 |
CSL Limited |
Anti-IL-13R alpha 1 antibodies and their uses thereof
|
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
|
CL2007003291A1
(es)
|
2006-11-15 |
2008-07-04 |
Medarex Inc |
Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
|
|
HU0700534D0
(en)
*
|
2006-11-24 |
2007-10-29 |
Mezoegazdasagi Biotechnologiai |
Transgenic animal with enhanced immune response and method for the preparation thereof
|
|
KR20150067395A
(ko)
|
2006-12-01 |
2015-06-17 |
메다렉스, 엘.엘.시. |
씨디22에 결합하는 인간 항체 및 이의 용도
|
|
JP2010513278A
(ja)
*
|
2006-12-13 |
2010-04-30 |
シェーリング コーポレイション |
Ｉｇｆ１ｒインヒビターを用いた癌の処置方法
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
NZ578354A
(en)
|
2006-12-14 |
2012-01-12 |
Medarex Inc |
Antibody-partner molecule conjugates that bind cd70 and uses thereof
|
|
CA2675233A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
|
SI2716301T1
(sl)
|
2007-02-16 |
2017-07-31 |
Merrimack Pharmaceuticals, Inc. |
Protitelesa proti ErbB3 in uporaba le-teh
|
|
WO2008108918A1
(en)
|
2007-02-21 |
2008-09-12 |
University Of Massachusetts |
Human antibodies against hepatitis c virus (hcv) uses thereof
|
|
MX2009009379A
(es)
*
|
2007-03-02 |
2009-09-14 |
Amgen Inc |
Metodos y composiciones para tratar enfermedades tumorales.
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
MY166021A
(en)
|
2007-03-22 |
2018-05-21 |
Biogen Ma Inc |
Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
FI20075278A0
(fi)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
|
|
CA2688275A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
|
CA2689695A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
|
PT2170956E
(pt)
|
2007-06-15 |
2015-02-05 |
Medigene Ag |
Tratamento de tumores utilizando um anticorpo anti-l1 específico
|
|
EP2023144A1
(en)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
|
AU2008317495B2
(en)
|
2007-08-02 |
2013-08-01 |
Novimmune S.A. |
Anti-RANTES antibodies and methods of use thereof
|
|
US9693539B2
(en)
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
|
CN101802008B
(zh)
|
2007-08-21 |
2015-04-01 |
安美基公司 |
人类c-fms抗原结合蛋白
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
ES2719728T3
(es)
|
2007-09-04 |
2019-07-12 |
Compugen Ltd |
Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
|
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
CA2700723A1
(en)
|
2007-09-26 |
2009-04-02 |
Amgen Inc. |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
WO2009056634A2
(en)
|
2007-11-02 |
2009-05-07 |
Novartis Ag |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
|
|
DK2224954T3
(en)
|
2007-11-07 |
2014-03-03 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
AU2008323206B2
(en)
|
2007-11-12 |
2014-08-14 |
U3 Pharma Gmbh |
AXL antibodies
|
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
|
EP2242771B1
(en)
|
2007-12-14 |
2013-07-17 |
Bristol-Myers Squibb Company |
Binding molecules to the human ox40 receptor
|
|
KR101615935B1
(ko)
|
2007-12-14 |
2016-04-28 |
노보 노르디스크 에이/에스 |
인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
|
|
NZ587506A
(en)
|
2008-01-25 |
2012-09-28 |
Univ Aarhus |
Selective exosite inhibition of papp-a activity against igfbp-4
|
|
CA2714071A1
(en)
|
2008-02-05 |
2009-08-13 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
|
TWI461210B
(zh)
|
2008-03-18 |
2014-11-21 |
Abbvie Inc |
治療牛皮癬的方法
|
|
US8557239B2
(en)
*
|
2009-09-14 |
2013-10-15 |
Abbvie Inc. |
Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
|
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
|
EP2732823B1
(en)
|
2008-06-25 |
2019-08-07 |
H. Lundbeck A/S |
Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain
|
|
BRPI0916668B1
(pt)
|
2008-08-05 |
2021-12-28 |
Novartis Ag |
Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
UA104297C2
(en)
|
2008-08-14 |
2014-01-27 |
Сефалон Острейлиа Пти Лтд |
Anti-il-12/il-23 antibody
|
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
|
MX2011003195A
(es)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
|
LT2346994T
(lt)
|
2008-09-30 |
2022-03-10 |
Ablexis, Llc |
Knock-in pelė, skirta chimerinių antikūnų gamybai
|
|
EP2348827B1
(en)
|
2008-10-27 |
2015-07-01 |
Revivicor, Inc. |
Immunocompromised ungulates
|
|
CN109045296A
(zh)
|
2008-11-10 |
2018-12-21 |
阿雷克森制药公司 |
用于治疗补体相关障碍的方法和组合物
|
|
LT2370463T
(lt)
|
2008-11-26 |
2016-12-12 |
Amgen Inc. |
Stabilizuotas aktivino iib receptoriaus variantas
|
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
US20110311450A1
(en)
|
2008-12-08 |
2011-12-22 |
Zurit Levine |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
EP2379593A2
(en)
|
2008-12-19 |
2011-10-26 |
H. Lundbeck A/S |
Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
|
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
|
UA102891C2
(uk)
|
2009-03-05 |
2013-08-27 |
Медарекс, Інк. |
Повні людські антитіла, специфічні до cadm1
|
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
|
EP3061463A1
(en)
|
2009-04-08 |
2016-08-31 |
LipUm AB |
New methods for treatment of inflammatory diseases
|
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
|
SG174273A1
(en)
|
2009-04-27 |
2011-10-28 |
Novartis Ag |
Compositions and methods for increasing muscle growth
|
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
|
DK2448970T3
(da)
|
2009-05-04 |
2014-10-06 |
Abbvie Res B V |
Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
|
|
SG175276A1
(en)
|
2009-05-05 |
2011-11-28 |
Novimmune Sa |
Anti-il-17f antibodies and methods of use thereof
|
|
US20120101262A1
(en)
|
2009-06-25 |
2012-04-26 |
Bristol-Myers Squibb Company |
Protein purification by caprylic acid (octanoic acid) precipitation
|
|
EP2564695B1
(en)
|
2009-07-08 |
2015-04-15 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2769473A1
(en)
|
2009-07-31 |
2011-02-03 |
N.V. Organon |
Fully human antibodies to btla
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
|
EP2480561B1
(en)
|
2009-09-23 |
2016-07-13 |
E. R. Squibb & Sons, L.L.C. |
Cation exchange chromatography
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
WO2011054359A2
(en)
|
2009-11-06 |
2011-05-12 |
University Of Copenhagen |
Method for early detection of cancer
|
|
NZ599813A
(en)
|
2009-11-09 |
2014-07-25 |
Alexion Pharma Inc |
Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
|
|
KR101806323B1
(ko)
|
2009-11-13 |
2017-12-07 |
다이이치 산쿄 유럽 게엠베하 |
Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
|
|
EP2499159B1
(en)
|
2009-11-13 |
2017-01-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
|
WO2011062926A2
(en)
|
2009-11-17 |
2011-05-26 |
Medarex, Inc. |
Methods for enhanced protein production
|
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
IN2012DN06309A
(enExample)
|
2010-01-11 |
2015-09-25 |
Alexion Pharma Inc |
|
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
|
KR101814571B1
(ko)
|
2010-03-10 |
2018-01-04 |
젠맵 에이/에스 |
Ｃ―ｍｅｔ에 대한 모노클로날 항체
|
|
RU2012144017A
(ru)
|
2010-03-17 |
2014-04-27 |
Эбботт Рисерч Б.В. |
Композиции антител против фактора роста нервов (ngf)
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
WO2011123708A2
(en)
|
2010-03-31 |
2011-10-06 |
Ablexis Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
|
MX2012012441A
(es)
|
2010-05-04 |
2013-02-26 |
Merrimack Pharmaceuticals Inc |
Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
|
|
ES2706412T3
(es)
|
2010-05-04 |
2019-03-28 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a CSF1R
|
|
WO2011138392A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
PE20130206A1
(es)
|
2010-05-06 |
2013-02-28 |
Novartis Ag |
Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
SI2580243T1
(sl)
|
2010-06-09 |
2020-02-28 |
Genmab A/S |
Protitelesa proti humanemu CD38
|
|
SMT201700547T1
(it)
|
2010-06-15 |
2018-01-11 |
Genmab As |
Coniugati di farmaco anticorpo umano contro il fattore tissutale
|
|
EP2585476A4
(en)
|
2010-06-22 |
2014-01-22 |
Neogenix Oncology Inc |
ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
US20120156130A1
(en)
|
2010-08-06 |
2012-06-21 |
Thore Hettmann |
Use of her3 binding agents in prostate treatment
|
|
ME02637B
(me)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
|
EP2622091B1
(en)
|
2010-09-23 |
2019-03-13 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
|
MX392780B
(es)
|
2010-10-13 |
2025-03-24 |
Janssen Biotech Inc |
Polinucléotidos que condifican anticuerpos de oncostatina m humana
|
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
|
TW201238973A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
|
WO2012088222A2
(en)
|
2010-12-21 |
2012-06-28 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
|
CA2824805A1
(en)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Il-27 antagonists for treating inflammatory diseases
|
|
US9315566B2
(en)
|
2011-01-24 |
2016-04-19 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
|
CA2826453A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
|
AU2012223358A1
(en)
|
2011-03-01 |
2013-09-05 |
Amgen Inc. |
Sclerostin and DKK-1 bispecific binding agents
|
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
|
US9499610B2
(en)
|
2011-04-08 |
2016-11-22 |
H. Lundbeck A/S |
Antibodies specific to pyroglutamated Aβ
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
CA2832387A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
EP2520292A1
(en)
|
2011-05-06 |
2012-11-07 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
EA036545B1
(ru)
|
2011-05-25 |
2020-11-20 |
Иннейт Фарма, С.А. |
Анти-kir антитела для лечения воспалительных заболеваний
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
CA2838340A1
(en)
|
2011-06-17 |
2012-12-20 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
|
US9428574B2
(en)
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
WO2013006437A1
(en)
|
2011-07-01 |
2013-01-10 |
Novartis Ag |
Method for treating metabolic disorders
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
US10323081B2
(en)
|
2011-07-06 |
2019-06-18 |
Genmag A/S |
Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
EP2734546A1
(en)
|
2011-07-18 |
2014-05-28 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
|
CN103945689B
(zh)
|
2011-09-19 |
2016-10-19 |
科马布有限公司 |
免疫球蛋白基因多样性的操纵及多抗体治疗剂
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
EP3653222A1
(en)
|
2011-10-14 |
2020-05-20 |
Novartis AG |
Antibodies and methods for wnt pathway-related diseases
|
|
DK2771364T3
(da)
|
2011-10-27 |
2019-08-19 |
Genmab As |
Fremstilling af heterodimere proteiner
|
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
US20140314667A1
(en)
|
2011-11-16 |
2014-10-23 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ES2758433T3
(es)
|
2011-12-05 |
2020-05-05 |
Novartis Ag |
Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
|
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
TW201329104A
(zh)
|
2011-12-08 |
2013-07-16 |
Amgen Inc |
人類ｌｃａｔ抗原結合蛋白質及其治療用途
|
|
EP2793925B1
(en)
|
2011-12-19 |
2019-03-20 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
AP2014007761A0
(en)
|
2011-12-21 |
2014-07-31 |
Novartis Ag |
Compositions and methods for antibodies targeting factor P
|
|
KR20140126357A
(ko)
|
2012-02-01 |
2014-10-30 |
컴퓨젠 엘티디. |
C1orf32 항체 및 이의 암 치료를 위한 용도
|
|
MY169341A
(en)
|
2012-02-06 |
2019-03-21 |
Inhibrx Inc |
Cd47 antibodies and methods of use thereof
|
|
KR102153374B1
(ko)
|
2012-03-15 |
2020-09-10 |
얀센 바이오테크 인코포레이티드 |
인간 항-cd27 항체, 방법 및 용도
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
DK2841456T3
(en)
|
2012-04-27 |
2018-08-13 |
Novo Nordisk As |
HUMAN CD30 LIGAND ANTI-BINDING PROTEINS
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
US9453080B2
(en)
|
2012-06-11 |
2016-09-27 |
Amgen Inc. |
Dual receptor antagonistic antigen-binding proteins and uses thereof
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
BR112014032276A2
(pt)
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
WO2014016737A1
(en)
|
2012-07-24 |
2014-01-30 |
Pfizer Inc. |
Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
|
KR20150047593A
(ko)
|
2012-08-31 |
2015-05-04 |
파이브 프라임 테라퓨틱스, 인크. |
집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
RU2670943C9
(ru)
|
2012-11-08 |
2018-11-26 |
Илэвэн Байотерапьютикс, Инк. |
Антагонисты ил-6 и их применение
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
CA2893767C
(en)
|
2012-12-05 |
2022-11-08 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
|
US20140186350A1
(en)
|
2012-12-18 |
2014-07-03 |
Novartis Ag |
Compositions and methods for long acting molecules
|
|
EP3336104A1
(en)
|
2012-12-28 |
2018-06-20 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
|
KR20210096697A
(ko)
|
2013-01-10 |
2021-08-05 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
EP3985024A1
(en)
|
2013-02-01 |
2022-04-20 |
Atara Biotherapeutics, Inc. |
Anti-activin-a compounds for the treatment of ovarian cancer
|
|
EP2953643B1
(en)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
|
AP2015008584A0
(en)
|
2013-02-08 |
2015-07-31 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
EP2970451A1
(en)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
UY35484A
(es)
|
2013-03-15 |
2014-10-31 |
Amgen Res Munich Gmbh |
Molécula de unión de cadena simple que comprenden ABP de extremo N
|
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
|
CN105143267B
(zh)
|
2013-03-15 |
2020-06-26 |
美国安进公司 |
人pac1抗体
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2014186878A1
(en)
|
2013-05-24 |
2014-11-27 |
Cashman Neil R |
Cell senescence markers as diagnostic and therapeutic targets
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
|
US20160200818A1
(en)
|
2013-08-14 |
2016-07-14 |
Novartis Ag |
Methods of treating Sporadic Inclusion Body Myositis
|
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
AU2014372309C1
(en)
|
2013-12-24 |
2017-12-14 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
NZ724815A
(en)
|
2014-04-04 |
2017-11-24 |
Bionomics Inc |
Humanized antibodies that bind lgr5
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
CA2951234C
(en)
|
2014-06-06 |
2022-05-31 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
MX389695B
(es)
|
2014-06-11 |
2025-03-20 |
Kathy A Green |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
SG11201610672YA
(en)
|
2014-06-23 |
2017-01-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
EP3160493A4
(en)
|
2014-06-26 |
2018-04-11 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
|
JP6913018B2
(ja)
|
2014-07-08 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
|
|
ME03665B
(me)
|
2014-07-11 |
2020-10-20 |
Genmab As |
Antitela koja vezuju axl
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
MX384418B
(es)
|
2014-07-31 |
2025-03-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
|
|
MX377344B
(es)
|
2014-07-31 |
2025-03-07 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
|
|
EP3174902B1
(en)
|
2014-08-01 |
2019-04-17 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
An anti-cd45rc antibody for use as drug
|
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
|
MA40512A
(fr)
|
2014-08-07 |
2021-03-24 |
Novartis Ag |
Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
|
|
SMT202200285T1
(it)
|
2014-08-11 |
2022-09-14 |
Acerta Pharma Bv |
Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
|
|
WO2016025331A1
(en)
|
2014-08-11 |
2016-02-18 |
University Of Massachusetts |
Anti-ospa antibodies and methods of use
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
AU2015318008B2
(en)
|
2014-09-15 |
2021-05-20 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
|
CA2963470A1
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
WO2016069727A1
(en)
|
2014-10-29 |
2016-05-06 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
WO2016073401A1
(en)
|
2014-11-03 |
2016-05-12 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
|
SG11201703667SA
(en)
|
2014-11-05 |
2017-06-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
|
MY185114A
(en)
|
2014-11-07 |
2021-04-30 |
Sesen Bio Inc |
Improved il-6 antibodies
|
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
KR20230125855A
(ko)
|
2014-11-21 |
2023-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73에 대항한 항체 및 그의 용도
|
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
EP3233912B1
(en)
|
2014-12-19 |
2021-05-19 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
|
TW201630937A
(zh)
|
2014-12-22 |
2016-09-01 |
戊瑞治療有限公司 |
用於治療ｐｖｎｓ之抗－ｃｓｆ１ｒ抗體
|
|
CN110256558B
(zh)
|
2014-12-23 |
2023-07-04 |
百时美施贵宝公司 |
针对tigit的抗体
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
AU2016233557B2
(en)
|
2015-03-13 |
2021-06-24 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
|
WO2016153983A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
|
WO2016153978A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran to enhance protein purification by affinity chromatography
|
|
CA2980460A1
(en)
|
2015-04-13 |
2016-10-20 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
|
AU2016273028B2
(en)
|
2015-06-05 |
2019-02-14 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
EA201890162A1
(ru)
|
2015-06-29 |
2018-07-31 |
Бристол-Маерс Сквибб Компани |
Антитела к cd40 с повышенной агонистической активностью
|
|
ME03772B
(me)
|
2015-07-10 |
2021-04-20 |
Genmab As |
Konjugati antitijela specifičnog za axl i lijeka za liječenje kancera
|
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
CA2994516A1
(en)
|
2015-08-03 |
2017-02-09 |
Novartis Ag |
Methods of treating fgf21-associated disorders
|
|
WO2017027685A2
(en)
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
EP3334761B1
(en)
|
2015-08-13 |
2023-07-19 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
WO2017042701A1
(en)
|
2015-09-09 |
2017-03-16 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
|
MA42821A
(fr)
|
2015-09-15 |
2018-07-25 |
Amgen Inc |
Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
AU2016353153B2
(en)
|
2015-11-12 |
2023-11-23 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
KR20250034528A
(ko)
|
2015-11-23 |
2025-03-11 |
파이브 프라임 테라퓨틱스, 인크. |
암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
|
|
FI3383920T3
(fi)
|
2015-11-30 |
2024-04-10 |
Univ California |
Kasvainspesifinen hyötyaineen antaminen ja immuuniaktivointi käyttämällä erittäin spesifiseen kasvainsolun pinta-antigeeniin kohdentuvaa ihmisen vasta-ainetta
|
|
US10556948B2
(en)
|
2015-11-30 |
2020-02-11 |
Bristol-Myers Squibb Company |
IP-10 antibodies and their uses
|
|
EP3390447A1
(en)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
|
CA3008102A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
MY197023A
(en)
|
2015-12-23 |
2023-05-22 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
PL3402503T3
(pl)
|
2016-01-13 |
2021-04-19 |
Acerta Pharma B.V. |
Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
|
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
|
|
CN108718522A
(zh)
|
2016-02-23 |
2018-10-30 |
赛森生物股份有限公司 |
Il-6拮抗剂制剂及其用途
|
|
KR20220033522A
(ko)
|
2016-03-04 |
2022-03-16 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
EP4406550A3
(en)
|
2016-03-04 |
2024-10-16 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
US10947317B2
(en)
|
2016-03-15 |
2021-03-16 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
KR20180138205A
(ko)
|
2016-03-22 |
2018-12-28 |
바이오노믹스 리미티드 |
항-lgr5 단클론성 항체의 투여
|
|
AU2017241776B2
(en)
|
2016-03-29 |
2024-06-20 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
BR112018071153A2
(pt)
|
2016-04-15 |
2019-04-16 |
Immunext, Inc. |
anticorpos anti-vista humano e uso dos mesmos
|
|
MX393066B
(es)
|
2016-04-18 |
2025-03-24 |
Celldex Therapeutics Inc |
Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
CA3023678A1
(en)
|
2016-05-09 |
2017-11-16 |
Bristol-Myers Squibb Company |
Tl1a antibodies and uses thereof
|
|
JP7231411B2
(ja)
|
2016-06-15 |
2023-03-01 |
ノバルティス アーゲー |
骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
|
|
JP2019519536A
(ja)
|
2016-07-01 |
2019-07-11 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
|
|
MY197836A
(en)
|
2016-07-12 |
2023-07-20 |
H Lundbeck As |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
|
SG10201911972QA
(en)
|
2016-07-14 |
2020-02-27 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
|
KR102579850B1
(ko)
|
2016-07-22 |
2023-09-18 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
|
CN118108847A
(zh)
|
2016-08-07 |
2024-05-31 |
诺华股份有限公司 |
mRNA介导的免疫方法
|
|
KR20190039978A
(ko)
|
2016-08-12 |
2019-04-16 |
브리스톨-마이어스 스큅 컴퍼니 |
단백질 정제 방법
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
JP2020500152A
(ja)
|
2016-09-30 |
2020-01-09 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
|
|
CR20190193A
(es)
|
2016-10-13 |
2019-08-21 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
|
|
EP3538551A4
(en)
|
2016-11-10 |
2020-11-11 |
Fortis Therapeutics, Inc. |
CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
|
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
|
RU2019114679A
(ru)
|
2016-11-15 |
2020-12-17 |
Х. Лундбекк А/С |
Средства, пути применения и способы лечения синуклеопатии
|
|
JP7645607B2
(ja)
|
2016-11-16 |
2025-03-14 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬を治療する方法
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN110072888B
(zh)
|
2016-12-16 |
2023-07-18 |
H.隆德贝克有限公司 |
药剂、用途和方法
|
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
|
KR20240134400A
(ko)
|
2016-12-23 |
2024-09-09 |
브리스톨-마이어스 스큅 컴퍼니 |
개선된 바이오분석 및 바이오프로세싱 성질을 위한 치료용 면역글로불린 g4의 디자인
|
|
CN110267985B
(zh)
|
2017-01-04 |
2023-05-23 |
H.隆德贝克有限公司 |
用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
|
|
CA3049110A1
(en)
|
2017-01-06 |
2018-07-12 |
Abl Bio Inc. |
Anti-.alpha.-syn antibody and use thereof
|
|
EA039807B1
(ru)
|
2017-01-06 |
2022-03-16 |
ЭйБиЭл БИО ИНК. |
Антитело к -синуклеину и его применение
|
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
CA3052095A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
IL319561A
(en)
|
2017-02-07 |
2025-05-01 |
Janssen Biotech Inc |
Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
|
|
KR102572663B1
(ko)
|
2017-02-08 |
2023-09-01 |
노파르티스 아게 |
Fgf21 모방 항체 및 이의 용도
|
|
EP3583124A1
(en)
|
2017-02-17 |
2019-12-25 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
|
IL269083B2
(en)
|
2017-03-24 |
2024-12-01 |
Novartis Ag |
Methods for preventing and treating heart disease
|
|
KR20230148855A
(ko)
|
2017-03-30 |
2023-10-25 |
더 존스 홉킨스 유니버시티 |
생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
|
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
PT3624837T
(pt)
|
2017-05-16 |
2025-10-01 |
Five Prime Therapeutics Inc |
Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
|
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EA201992502A1
(ru)
|
2017-06-20 |
2020-04-22 |
Эмджен Инк. |
Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
|
WO2018237095A1
(en)
|
2017-06-21 |
2018-12-27 |
Amgen Inc. |
METHOD OF TREATING OR ENHANCING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR AGONIST FUSION PROTEINS FROM THE GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) / GLP-1 RECEPTOR
|
|
TW201906865A
(zh)
|
2017-06-28 |
2019-02-16 |
瑞士商諾華公司 |
預防及治療尿失禁之方法
|
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
|
EP4464719A3
(en)
|
2017-08-04 |
2025-03-05 |
Amgen Inc. |
Method of conjugation of cys-mabs
|
|
US20200256880A1
(en)
|
2017-08-16 |
2020-08-13 |
The Broad Institute, Inc. |
Neuronal Assay Method Involving Calcineurin
|
|
KR102767190B1
(ko)
|
2017-08-18 |
2025-02-11 |
더 존스 홉킨스 유니버시티 |
단백질 정제를 위한 초분자 필라멘트 조립체
|
|
SG11202001606XA
(en)
|
2017-09-13 |
2020-03-30 |
Five Prime Therapeutics Inc |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
KR20240170590A
(ko)
|
2017-11-06 |
2024-12-03 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선성 관절염을 치료하는 안전하고 유효한 방법
|
|
EP3720279B1
(en)
|
2017-12-05 |
2022-09-21 |
Regeneron Pharmaceuticals, Inc. |
Mice having an engineered immunoglobulin lambda light chain and uses thereof
|
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
|
CN116731173A
(zh)
|
2017-12-14 |
2023-09-12 |
Abl生物公司 |
抗a-syn/igf1r的双特异性抗体及其用途
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
EP3737699A1
(en)
|
2018-01-12 |
2020-11-18 |
Amgen Inc. |
Pac1 antibodies and uses thereof
|
|
CN111886255B
(zh)
|
2018-01-12 |
2025-04-04 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
|
CN111770936A
(zh)
|
2018-01-12 |
2020-10-13 |
百时美施贵宝公司 |
抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
|
|
JP7516250B2
(ja)
|
2018-03-05 |
2024-07-16 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
WO2019191416A1
(en)
|
2018-03-29 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
|
KR102882368B1
(ko)
|
2018-05-07 |
2025-11-07 |
젠맵 에이/에스 |
항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
|
TW202010755A
(zh)
|
2018-05-07 |
2020-03-16 |
丹麥商珍美寶股份有限公司 |
使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
|
|
WO2019215701A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of treating depression using il-23 antibodies
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
CN113056483B
(zh)
|
2018-07-09 |
2025-08-01 |
戊瑞治疗有限公司 |
结合到ilt4的抗体
|
|
JP7634474B2
(ja)
|
2018-07-18 |
2025-02-21 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
|
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
|
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
|
MX2021002332A
(es)
|
2018-08-27 |
2021-08-11 |
Affimed Gmbh |
Células nk crioreservadas precargadas con una construcción de anticuerpo.
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
CN113056487A
(zh)
|
2018-09-18 |
2021-06-29 |
梅里麦克制药股份有限公司 |
抗tnfr2抗体及其用途
|
|
CZ38255U1
(cs)
|
2018-09-24 |
2024-11-20 |
Janssen Biotech, Inc |
Protilátka proti IL-12/IL-23p40 pro použití při způsobu léčení středně až závažně aktivní vředové kolitidy
|
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
WO2020097627A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
|
JP7520003B2
(ja)
|
2018-11-16 |
2024-07-22 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｎｋｇ２ａ抗体およびその使用
|
|
IL283192B2
(en)
|
2018-11-20 |
2025-10-01 |
Janssen Biotech Inc |
A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
|
|
EP3897722A4
(en)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES
|
|
AU2020208828A1
(en)
|
2019-01-15 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
|
CN113396162B
(zh)
|
2019-01-22 |
2024-08-16 |
百时美施贵宝公司 |
抗IL-7Rα亚基的抗体及其用途
|
|
BR112021014267A2
(pt)
|
2019-01-23 |
2022-02-15 |
Janssen Biotech Inc |
Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
|
|
CA3131953A1
(en)
|
2019-03-01 |
2020-09-10 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
JP7662529B2
(ja)
|
2019-03-14 |
2025-04-15 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｔｎｆ抗体組成物を産生するための方法
|
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
|
CA3134079A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
|
|
CN113646630B
(zh)
|
2019-03-29 |
2024-05-07 |
百时美施贵宝公司 |
测量色谱树脂的疏水性的方法
|
|
MX2021014302A
(es)
|
2019-05-23 |
2022-01-04 |
Janssen Biotech Inc |
Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
|
|
TWI879770B
(zh)
|
2019-05-30 |
2025-04-11 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
|
JP2022536088A
(ja)
|
2019-06-04 |
2022-08-12 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
|
|
CN119613549A
(zh)
|
2019-06-12 |
2025-03-14 |
诺华股份有限公司 |
利钠肽受体1抗体及使用方法
|
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
AU2020304671A1
(en)
|
2019-06-28 |
2022-01-20 |
Amgen Inc. |
Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
|
|
BR112021005478A2
(pt)
|
2019-07-24 |
2021-06-15 |
H. Lundbeck A/S |
anticorpos anti-mglur5 e uso dos mesmos
|
|
AU2020323901A1
(en)
|
2019-07-26 |
2022-02-24 |
Amgen Inc. |
Anti-IL13 antigen binding proteins
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
|
JP7686626B2
(ja)
|
2019-09-10 |
2025-06-02 |
アムジエン・インコーポレーテツド |
増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
|
CA3160151A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
BR112022008661A2
(pt)
|
2019-11-07 |
2022-07-19 |
Genmab As |
Método para tratar câncer em um sujeito, conjugado de anticorpo-fármaco que se liga ao fator de tecido, uso de um conjugado de anticorpo-fármaco, e, kit
|
|
EP4628498A2
(en)
|
2019-11-08 |
2025-10-08 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
|
EP4077376A2
(en)
|
2019-12-19 |
2022-10-26 |
Quidel Corporation |
Monoclonal antibody fusions
|
|
CN115135671A
(zh)
|
2019-12-20 |
2022-09-30 |
新石生物制药有限公司 |
抗白介素-23 p19的抗体及其使用方法
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
KR20220119467A
(ko)
|
2019-12-27 |
2022-08-29 |
아피메트 게엠베하 |
이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
|
|
TWI867138B
(zh)
|
2020-01-06 |
2024-12-21 |
美商高誠生物醫藥股份有限公司 |
抗tnfr2抗體及其用途
|
|
JP7719799B2
(ja)
|
2020-01-07 |
2025-08-06 |
ハイファイバイオ， インコーポレイテッド |
抗ガレクチン－９抗体およびその使用
|
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
CN115427454A
(zh)
|
2020-03-19 |
2022-12-02 |
安进公司 |
针对粘蛋白17的抗体及其用途
|
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
|
IL297906A
(en)
|
2020-05-05 |
2023-01-01 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
WO2021243320A2
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
|
CA3183898A1
(en)
|
2020-06-29 |
2022-01-06 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2022013745A1
(en)
|
2020-07-13 |
2022-01-20 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
CA3190230A1
(en)
|
2020-07-30 |
2022-02-03 |
Janssen Biotech, Inc. |
Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
|
|
IL300528A
(en)
|
2020-08-07 |
2023-04-01 |
Fortis Therapeutics Inc |
Immune conjugates targeting cd46 and methods of using them
|
|
MX2023001707A
(es)
|
2020-08-10 |
2023-05-04 |
Shanghai Xunbaihui Biotechnology Co Ltd |
Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
|
|
CA3191710A1
(en)
|
2020-08-20 |
2022-02-24 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
MX2023004088A
(es)
|
2020-10-07 |
2023-04-27 |
Amgen Inc |
Seleccion racional de bloques de construccion para el ensamblaje de anticuerpos multiespecificos.
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
|
CA3199931A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced clipping rate
|
|
KR20230104256A
(ko)
|
2020-11-06 |
2023-07-07 |
암젠 인크 |
증가된 선택성의 다중표적화 이중특이적 항원 결합 분자
|
|
CR20230235A
(es)
|
2020-11-06 |
2023-10-05 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
US20240002545A1
(en)
|
2020-11-10 |
2024-01-04 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
|
US20240024320A1
(en)
|
2020-11-17 |
2024-01-25 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
|
WO2022130182A1
(en)
|
2020-12-14 |
2022-06-23 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
|
WO2022220603A1
(ko)
|
2021-04-16 |
2022-10-20 |
고려대학교 산학협력단 |
코로나-19 바이러스 표적 인간 항체
|
|
MX2023012324A
(es)
|
2021-04-20 |
2023-10-30 |
Amgen Inc |
Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
|
|
EP4330281A1
(en)
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
KR20240034215A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
|
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
|
EP4367136A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
US20250179182A1
(en)
|
2021-10-29 |
2025-06-05 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody drug conjugate
|
|
IL312060A
(en)
|
2021-11-03 |
2024-06-01 |
Affimed Gmbh |
Bispecific CD16A binders
|
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
|
AU2022388887A1
(en)
|
2021-11-15 |
2024-07-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
EP4499689A1
(en)
|
2022-03-30 |
2025-02-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
EP4518904A1
(en)
|
2022-05-06 |
2025-03-12 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
|
EP4522651A1
(en)
|
2022-05-12 |
2025-03-19 |
Amgen Research (Munich) GmbH |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
KR20250011938A
(ko)
|
2022-05-18 |
2025-01-22 |
얀센 바이오테크 인코포레이티드 |
Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
|
|
CA3261603A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
ANTIBODY-DRUG CONJUGATES
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
CN120569403A
(zh)
|
2022-11-22 |
2025-08-29 |
詹森生物科技公司 |
用抗il23特异性抗体治疗溃疡性结肠炎的方法
|
|
EP4634226A1
(en)
|
2022-12-16 |
2025-10-22 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
UY40797A
(es)
|
2023-06-14 |
2024-12-31 |
Amgen Inc |
Moléculas captadoras de enmascaramiento de células t
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025147576A1
(en)
|
2024-01-06 |
2025-07-10 |
Generate Biomedicines, Inc. |
Anti-il-13 antibodies and methods of use thereof
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025160161A1
(en)
|
2024-01-23 |
2025-07-31 |
Amgen Inc. |
Methods for modulating monoclonal antibody charge variants
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025199030A1
(en)
|
2024-03-18 |
2025-09-25 |
Amgen Inc. |
Glp-1 receptor agonists and their medical use
|
|
WO2025196691A1
(en)
|
2024-03-20 |
2025-09-25 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2025255405A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Anti-fap antibodies and uses thereof
|
|
WO2025255349A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|